LOGIN / SKAPA KONTO
Aktuellt
SUMMARY Do patients with greater knowledge manage their disease better? This question was addressed in a cross sectional study presented at ERS2025. A new framework from Professor Celeste Porsbjerg’s team redefines remission in severe...
This was the resounding message from a recent international panel moderated by Dr. Liz Steve, a UK-based health psychologist, at the ERS Congress 2025. The session brought together patient advocates and clinical experts to...
In modern care, patients are expected to be empowered and to actively participate in decision making regarding their own healthcare. And on top, they are expected to make informed decisions, which for some patients require learning...
A preview of new insights into COPD and comorbidities Global leading researchers —strongly represented by the Nordics—presented compelling findings on chronic obstructive pulmonary disease (COPD) and its complex interplay with cardiovascular, metabolic, genetic, and...
SUMMARY Why we still need to address inhalation technique. Effective inhaler therapy hinges on matching the right device to the right patient—and ensuring proper technique through training. As sustainability goals evolve, clinical decisions must...
SUMMARY Are eosinophils in COPD truly a marker of type 2 (T2) inflammation, or do they simply reflect underlying or misclassified asthma? Presentation COPD: pathobiological features supporting the case for a T2 trait Speaker:...
SUMMARY Some get off to a bad start, others simply do not realize they have a disease. And others fall into the trap of thinking that tobacco exposure could be too low to cause...
SUMMARY Many preventable respiratory hazards are both a cause and a consequence of climate change. Fine particulate matter, especially from wildfires and indoor sources, poses serious health risks and disproportionately affects vulnerable populations. Targeted...
SUMMARY Lifelong exposure to environmental factors — especially air pollution — significantly affects the risk and progression of chronic lung diseases, and understanding these interactions is key for early intervention and personalized prevention strategies....
Clinical remission in adults with moderate-to-severe asthma A new framework from Professor Celeste Porsbjerg’s team redefines remission in severe asthma by focusing on disease activity, not damage. Early, targeted treatment during the “at-risk asthma”...
Chiesi er et familieeid legemiddelselskap grunnlagt i 1935. Vi tror på innovasjon, ansvar og menneskelig empati. Vår lidenskap er å forbedre livskvaliteten for pasienter over hele verden gjennom forskning, utvikling og bærekraftige løsninger.
© 2026 Chiesi Pharma AB. Dette nettstedet er beregnet på helsepersonell i Norge.